MarketPulse

TL1A inhibitor

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Duvakitug Shows Sustained Remission in Phase 2b Trial for Inflammatory Bowel Disease

Teva and Sanofi's duvakitug showed sustained remission in phase 2b trial for inflammatory bowel disease, with remission rates of 41-58% depending on condition and dosage.
SNYTEVAmonoclonal antibodyinflammatory bowel disease
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi And Teva

Sanofi, Teva Report Sustained Efficacy for TL1A Inhibitor in IBD Phase 2b Trial

Sanofi and Teva's duvakitug showed sustained efficacy treating ulcerative colitis and Crohn's disease in a Phase 2b trial, supporting advancement to Phase 3 development.
SNYTEVAmonoclonal antibodyinflammatory bowel disease
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi And Teva

Sanofi and Teva Report Sustained Efficacy for Duvakitug in IBD Maintenance Study

Sanofi and Teva report duvakitug maintains efficacy in IBD maintenance trial, with remission rates of 47-58% in ulcerative colitis. Drug advances to Phase III development.
SNYTEVAmonoclonal antibodyinflammatory bowel disease